Drug pricing

NHS England strikes deal with Orkambi manufacturer

Patients in England with cystic fibrosis will now have access to three new cystic fibrosis drugs on the NHS, following an agreement between the manufacturer and the government.…

No-deal Brexit likely to increase cost of new medicines, Scottish government says

The Scottish government has said it is “likely that the cost of new medicines in the UK will increase” under a no-deal Brexit.…

Competition and Markets Authority accepts £8m from drug firm accused of price fixing

The Competition and Markets Authority has accepted an offer of £8m to be paid to the NHS by a drug manufacturer as part of an agreement following allegations of anticompetitive behaviour and the supply of a prescription drug.…

Government reforms of Category M reimbursement risk ‘exacerbating’ drug shortages, says PSNC

The government risks making drugs shortages worse with its generics reimbursement reforms, unless the proposals are rolled out gradually, the Pharmaceutical Services Negotiating Committee has said.…

Drug manufacturer offers to pay NHS £8m to resolve CMA allegations of anti-competitive behaviour

A drug manufacturer has offered to pay the NHS £8m to resolve concerns around allegations of anti-competitive behaviour over the supply of a prescription drug.…

CMA accuses four pharmaceutical companies of breaking competition law on supply of antidepressant

The Competition and Markets Authority has provisionally found four pharmaceutical companies to have broken completion law in relation to supply of nortriptyline, a tricyclic antidepressant.…

MS drug approved by NICE after NHS renegotiates price

A new drug to treat some adults with multiple sclerosis is now being recommended for use by the National Institute for Health and Care Excellence after the NHS renegotiated a lower price with the manufacturer Roche.…

Government delays consultation with pharmaceutical industry over generics price limiting powers

A government consultation with the pharmaceutical industry over plans to use new powers to limit the price of generic medicines has been delayed until later in 2019, the Department of Health and Social Care has said.…

Government cap on branded medicine prices may be unsustainable, warns ABPI

An ongoing cap on the price of branded medicines to the NHS “may not be sustainable” in the long term, the Association of the British Pharmaceutical Industry has said.…

Government slashes annual spend on generic price concessions by half in just one year

The Department of Health and Social Care has halved its expenditure on price concessions in the past year, according to a recent analysis.…